< Zurück zu den aktuellen Neuigkeiten & Events

UPC

UPC – Preparatory Committee Proposes Court Fees

Mai 2015

Over 2 years after the Agreement on the Unitary Patent Court was signed, the Preparatory Committee has published proposed Court fees and launched a public consultation on the fee structure for the Court.

The consultation document comprises of two options revising the Rules of Procedure, including a table of fees, a scale of ceilings for recoverable costs and an Explanatory Note.

The Committee have said that “The fee structure for the Unified Patent Court will comprise fixed fees and, for certain actions, an additional value based fee. The fee levels proposed are the lowest that will enable eventual sustainability of the Court”. Two alternatives have been set out.

Given that the Unitary Patent and UPC have been championed by the European Parliament to “cut costs for small firms and tailored the regime to their needs…” it may be surprising that both the proposed alternatives include a minimum fixed fee of €11, 000 to bring an infringement action before the UPC. Furthermore, for claims with a value greater than €500,000, a value-based fee will also be payable (increasing with value of the action). Counter claims for revocation have the same fixed fee, and revocations, higher still at €20,000. Ceiling levels for recoverable costs are also proposed, starting at €50,000 for a €250, 000 action.

There are options for seeking reductions; in one alterative, reimbursements may be available if the action is settled or withdrawn and in the other alternative, SMEs, micro entities and the like, may apply for an exemption (this will only apply to the value based fees).

More welcome news will be the proposal that an opt-out fee, to remove a European patent from the jurisdiction of the UPC, should be set at €80, and this will be applicable to each patent, and not each designation. Comments (electronically to the secretariat@unified-patent-court.org before midnight on the 31 July) are welcomed on any aspect of the proposal and will be considered by the Preparatory Committee and its appropriate Working Groups prior to publication of an agreed fee structure.

Aktuelle Neuigkeiten

Event - 10. September 2025

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Veranstaltungsdetails

EU Customs Recordals

Weiterlesen

HGF Partners Recognised in IAM Strategy 300 2025

The latest edition of IAM Strategy 300: The World’s Leading IP Strategists has now been published, and HGF is proud to announce that three of our partners have been listed …

Weiterlesen
Event - 25. September 2025

HGF Futures Life Sciences – Join our open day in London

An opportunity to discover your path to becoming a Life Science Patent Attorney! Are you a recent or soon-to-be graduate with a degree in Life Sciences? Are you passionate about …

Veranstaltungsdetails

Celebrating exam success at HGF

We would like to congratulate our colleagues on their recent exam success. Their dedication, perseverance, and commitment to professional development have led to success, and we are pleased to celebrate …

Weiterlesen
Event - 5. November 2025

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. The IAM Live Navigating the UPC will take place at the Marriott Opera Ambassador Hotel, Paris on 5th …

Veranstaltungsdetails

Post Sale Confusion – dupes and lookalikes beware?

Last month, the UK Supreme Court issued its highly-anticipated decision in Iconix Luxembourg Holdings SARL v Dream Pairs Europe Inc and another [2025] UKSC 25. Helpful background to the dispute …

Weiterlesen

Ein wegweisender Fall – Vorsicht vor Sequenzfehlern in Patentansprüchen

Samsung Bioepis UK Ltd gegen Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Richter Meade – 20. Mai 2025 Das britische Patentgericht hat entschieden, dass die Eculizumab-Biosimilars von Samsung Bioepis …

Weiterlesen